Evidence map›Paper›PMID 37744341›Full record

ArticleFrontiers in immunology2023

Impact of the TLR4 agonist BECC438 on a novel vaccine formulation against

Ti Lu, Sayan Das, Debaki R Howlader, Akshay Jain, Gang Hu, Zackary K Dietz, Qi Zheng, Siva Sai Kumar Ratnakaram, Sean K Whittier, David J Varisco and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. International journal of molecular sciences · 2024
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ti LuDepartment of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, United States.
Sayan DasDepartment of Microbial Pathogenesis, School of Dentistry, University of Maryland, Baltimore, MD, United States.
Debaki R HowladerDepartment of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, United States.
Akshay JainDepartment of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, United States.
Gang HuDepartment of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, United States.
Zackary K DietzDepartment of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, United States.
Qi ZhengDepartment of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, United States.
Siva Sai Kumar RatnakaramDepartment of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, United States.
Sean K WhittierDepartment of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, United States.
David J VariscoDepartment of Microbial Pathogenesis, School of Dentistry, University of Maryland, Baltimore, MD, United States.
Robert K ErnstDepartment of Microbial Pathogenesis, School of Dentistry, University of Maryland, Baltimore, MD, United States.
William D PickingDepartment of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, United States.
Wendy L PickingDepartment of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, United States.

Funding

Vaccines to counter emerging antibiotic resistance (R01AI138970)R01AI138970 · NIAID · UNIVERSITY OF MISSOURI-COLUMBIA · PI PICKING, WENDY L. · 2018 to 2022
$6.0M
NIAID NIH HHS HHSN272201800043CNIAID NIH HHS R01 AI138970
6 · The paper itself

Abstract

Shigellosis (bacillary dysentery) is a severe gastrointestinal infection with a global incidence of 90 million cases annually. Despite the severity of this disease, there is currently no licensed vaccine against shigellosis.

Indexed as

Antigens, BacterialDysentery, BacillaryShigella VaccinesToll-Like Receptor 4Adjuvants, ImmunologicAdjuvants, VaccineAnimalsAntibodies, BacterialBacterial ProteinsBacterial ToxinsDisease Models, AnimalEnterotoxinsEscherichia coli ProteinsFemaleHumansMiceAdjuvants, ImmunologicAdjuvants, VaccineAntibodies, BacterialAntigens, BacterialBacterial ProteinsBacterial ToxinsEnterotoxinsEscherichia coli Proteinsheat-labile enterotoxin, E coliipaB protein, ShigellaIpaD protein, Shigella flexneriShigella VaccinesTlr4 protein, mouseToll-Like Receptor 4IFN-gammaIL-17ShigellaT3SSvaccine

Identifiers

PMID37744341
PMCPMC10512073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.